Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation

Gut

Volumn 59, Issue 4, 2010, Pages 521-530

  Baghdasaryan, Anna ^a   Claudel, Thierry ^a   Kosters, Astrid ^b   Gumhold, Judith ^a   Silbert, Dagmar ^a   Thüringer, Andrea ^a   Leski, Katharina ^a   Fickert, Peter ^a   Karpen, Saul J ^b,c   Trauner, Michael ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Division of Maternal Fetal Medicine   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; GLUTATHIONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; BILE FLOW; CELL PROLIFERATION; CHOLESTASIS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; FIBROGENESIS; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIVER FIBROSIS; LIVER INJURY; MALE; MOUSE; MOUSE STRAIN; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCLEROSING CHOLANGITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BILE; BILE ACIDS AND SALTS; BILE DUCTS; CELL PROLIFERATION; CELLS, CULTURED; CHOLANGITIS, SCLEROSING; CURCUMIN; DRUG EVALUATION, PRECLINICAL; EPITHELIAL CELLS; FIBROBLASTS; INFLAMMATION MEDIATORS; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; P-GLYCOPROTEINS; PPAR GAMMA; SIGNAL TRANSDUCTION;

EID: 77950798963     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.186528     Document Type: Article

References (69)

1. Silveira MG, Lindor KD. Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol 2008;14:3338-3349
2. Michaels A, Levy C. The medical management of primary sclerosing cholangitis. Medscape J Med 2008;10:61. (Pubitemid 351552206)
3. Alvaro D, Mancino MG. New insights on the molecular and cell biology of human cholangiopathies. Mol Aspects Med 2008;29:50-57
4. Alvaro D, Mancino MG, Glaser S, et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 2007;132:415-431 (Pubitemid 46108729)
5. Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 2004;127:1565-1577
6. Aggarwal BB, Bhatt ID, Ichikawa H, et al. Curcumin - biological and medicinal properties. 2006:297-368. http://www.indsaff.com/ 10%20Curcumin%20biological.pdf (accessed 10 November 2008).
7. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 2008;75:787-809.
8. Jain SK. Ethnobotany and research on medicinal plants in India. Ciba Found Symp 1994;185:153-164
9. Maheshwari RK, Singh AK, Gaddipati J, et al. Multiple biological activities of curcumin: a short review. Life Sci 2006;78:2081-2087
10. Oppenheimer A. Turmeric (curumin) in biliary diseases. Lancet 1937:619-621
11. Rasyid A, Lelo A. The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther 1999;13:245-249 (Pubitemid 29090021)
12. Fu Y, Zheng S, Lin J, et al. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol 2008;73:399-409. (Pubitemid 351159210)
13. Reyes-Gordillo K, Segovia J, Shibayama M, et al. Curcumin prevents and reverses cirrhosis induced by bile duct obstruction or CCl4 in rats: role of TGF-beta modulation and oxidative stress. Fundam Clin Pharmacol 2008;22:417-427
14. Reyes-Gordillo K, Segovia J, Shibayama M, et al. Curcumin protects against acute liver damage in the rat by inhibiting NF-kappaB, proinflammatory cytokines production and oxidative stress. Biochim Biophys Acta 2007;1770:989-996 (Pubitemid 46621136)
15. Zhao ZS, O'Brien PJ. The prevention of CCl4-induced liver necrosis in mice by naturally occurring methylenedioxybenzenes. Toxicol Appl Pharmacol 1996;140:411-421
16. Li D, Zimmerman TL, Thevananther S, et al. Interleukin-1 beta-mediated suppression of RXR: RAR transactivation of the Ntcp promoter is JNK-dependent. J Biol Chem 2002;277:31416-31422 (Pubitemid 34968941)
17. Fickert P, Fuchsbichler A, Wagner M, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004;127:261-274 (Pubitemid 38962293)
18. Fickert P, Wagner M, Marschall HU, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006;130:465-481 (Pubitemid 43202044)
19. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 2003;83:633-671 (Pubitemid 36378680)
20. Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 2007;27:77-98. (Pubitemid 46269806)
21. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998;339:1217-1227
22. -/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol 2005;43:1045-1054
23. Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 1981;112:70-75
24. Trauner M, Arrese M, Soroka CJ, et al. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 1997;113:255-264 (Pubitemid 27281782)
25. Fickert P, Zollner G, Fuchsbichler A, et al. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 2001;121:170-183 (Pubitemid 32591527)
26. Zollner G, Fickert P, Silbert D, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003;38:717-727 (Pubitemid 36613336)
27. Wagner M, Fickert P, Zollner G, et al. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 2003;125:825-838 (Pubitemid 37070700)
28. Uchio K, Tuchweber B, Manabe N, et al. Cellular retinol-binding protein-1 expression and modulation during in vivo and in vitro myofibroblastic differentiation of rat hepatic stellate cells and portal fibroblasts. Lab Invest 2002;82:619-628 (Pubitemid 34522374)
29. Trauner M, Fickert P, Halilbasic E, et al. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med Wochenschr 2008;158:542-548
30. Chen A, Zheng S. Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cells in vitro by blocking NF-kappaB and ERK signalling. Br J Pharmacol 2008;153:557-567 (Pubitemid 351199009)
31. Hazra S, Xiong S, Wang J, et al. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 2004;279:11392-11401 (Pubitemid 38401638)
32. Hellerbrand C, Jobin C, Iimuro Y, et al. Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor. Hepatology 1998;27:1285-1295 (Pubitemid 28227855)
33. Hellerbrand C, Jobin C, Licato LL, et al. Cytokines induce NF-kappaB in activated but not in quiescent rat hepatic stellate cells. Am J Physiol 1998;275:G269-78. (Pubitemid 128734895)
34. Marra F, Efsen E, Romanelli RG, et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000;119:466-478 (Pubitemid 30621997)
35. Marra F, DeFranco R, Grappone C, et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 1998;152:423-430 (Pubitemid 28106388)
36. Osborn L, Hession C, Tizard R, et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989;59:1203-1211 (Pubitemid 20024630)
37. Kelly M, Hwang JM, Kubes P. Modulating leukocyte recruitment in inflammation. J Allergy Clin Immunol 2007;120:3-10.
38. Cullen SN, Rust C, Fleming K, et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008;48:792-800.
39. De Maria N, Colantoni A, Rosenbloom E, et al. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepatogastroenterology 1996;43:1472-1479 (Pubitemid 27007335)
40. Gong Y, Huang ZB, Christensen E, et al. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2008(3):CD000551. doi:10.1002/14651858.CD000551.pub2
41. Shi J, Wu C, Lin Y, et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006;101:1529-1538 (Pubitemid 43980627)
42. Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001;7:1894-1900. (Pubitemid 32994823)
43. Henning NaK O. Untersuchungen über Resorption und Ausscheidung des Curcumins. Münchener Medizinische Wochenschrift 1934;42:1611.
44. Chen C, Johnston TD, Wu G, et al. Curcumin has potent liver preservation properties in an isolated perfusion model. Transplantation 2006;82:931-937 (Pubitemid 44564040)
45. Deters M, Siegers C, Muhl P, et al. Choleretic effects of curcuminoids on an acute cyclosporin-induced cholestasis in the rat. Planta Med 1999;65:610-613 (Pubitemid 29503226)
46. Hussain MS, Chandrasekhara N. Effect on curcumin on cholesterol gall-stone induction in mice. Indian J Med Res 1992;96:288-291 (Pubitemid 23034678)
47. Jacob A, Wu R, Zhou M, et al. Mechanism of the anti-inflammatory effect of curcumin: ppar-gamma activation. PPAR Res 2007;2007:89369. (Pubitemid 351171859)
48. Lin J, Chen A. Activation of peroxisome proliferator-activated receptor-gamma by curcumin blocks the signaling pathways for PDGF and EGF in hepatic stellate cells. Lab Invest 2008;88:529-540 (Pubitemid 351581455)
49. Xu J, Fu Y, Chen A. Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol 2003;285:G20-30.
50. Zheng S, Chen A. Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J 2004;384:149-157 (Pubitemid 39564171)
51. Zheng S, Chen A. Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor-gamma in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2007;292:G113-123. (Pubitemid 46090257)
52. Zhou Y, Zheng S, Lin J, et al. The interruption of the PDGF and EGF signaling pathways by curcumin stimulates gene expression of PPARgamma in rat activated hepatic stellate cell in vitro. Lab Invest 2007;87:488-498 (Pubitemid 46633122)
53. Marra F, DeFranco R, Robino G, et al. Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. World J Gastroenterol 2005;11:4931-4938 (Pubitemid 41227188)
54. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218
55. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247-2250
56. Cassiman D, Libbrecht L, Desmet V, et al. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol 2002;36:200-209 (Pubitemid 34146426)
57. Eng FJ, Friedman SL. Fibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex. Am J Physiol Gastrointest Liver Physiol 2000;279:G7-G11.
58. Hazra S, Miyahara T, Rippe RA, et al. PPAR gamma and hepatic stellate cells. Comp Hepatol 2004;3(Suppl 1):S7.
59. Mann DA, Smart DE. Transcriptional regulation of hepatic stellate cell activation. Gut 2002;50:891-896 (Pubitemid 34539057)
60. Miyahara T, Schrum L, Rippe R, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000;275:35715-35722
61. Galli A, Crabb D, Price D, et al. Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells. Hepatology 2000;31:101-108 (Pubitemid 30033695)
62. Galli A, Crabb DW, Ceni E, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002;122:1924-1940 (Pubitemid 34651436)
63. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008;269:199-225.
64. Maher JJ, Lozier JS, Scott MK. Rat hepatic stellate cells produce cytokine-induced neutrophil chemoattractant in culture and in vivo. Am J Physiol 1998;275:G847-53.
65. Cheng Y, Ping J, Xu LM. Effects of curcumin on peroxisome proliferator-activated receptor gamma expression and nuclear translocation/ redistribution in culture-activated rat hepatic stellate cells. Chin Med J (Engl) 2007;120:794-801. (Pubitemid 46767827)
66. O'Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 2006;26:3-21.
67. Chapman R, Cullen S. Etiopathogenesis of primary sclerosing cholangitis. World J Gastroenterol 2008;14:3350-3359
68. Safadi R, Ohta M, Alvarez CE, et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004;127:870-882 (Pubitemid 39208419)
69. Muhanna N, Horani A, Doron S, et al. Lymphocyte-hepatic stellate cell proximity suggests a direct interaction. Clin Exp Immunol 2007;148:338-347 (Pubitemid 46587597)